These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16585022)

  • 61. Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?
    Callaghan MU; Rajpurkar M; Chitlur M; Warrier I; Lusher J
    Haemophilia; 2011 May; 17(3):483-9. PubMed ID: 21118335
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.
    Carpenter SL; Khair K; Gringeri A; Valentino LA
    Haemophilia; 2018 Jul; 24(4):570-577. PubMed ID: 29901839
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
    Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
    Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?
    Di Minno G; Coppola A
    Haemophilia; 2013 Jan; 19 Suppl 1():18-23. PubMed ID: 23278996
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hemophilia treatment. Immune tolerance induction: prospective clinical trials.
    Hay CR
    Haematologica; 2000 Oct; 85(10 Suppl):52-5; discussion 55-6. PubMed ID: 11187872
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.
    Rocino A; de Biasi R
    Vox Sang; 1999; 77 Suppl 1():65-9. PubMed ID: 10529692
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
    Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
    Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
    Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
    [TBL] [Abstract][Full Text] [Related]  

  • 71. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

  • 73. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review.
    Luna-Záizar H; González-Alcázar JÁ; Evangelista-Castro N; Aguilar-López LB; Ruiz-Quezada SL; Beltrán-Miranda CP; Jaloma-Cruz AR
    Blood Cells Mol Dis; 2018 Jul; 71():45-52. PubMed ID: 29544691
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors.
    Batlle J; Lopez MF; Brackmann HH; Gaillard S; Goudemand J; Humbert J; De Moerloose P; Maass E; Mauz-Körholz C; Sultan Y; Stieltjes N
    Haemophilia; 1999 Nov; 5(6):431-5. PubMed ID: 10583531
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient.
    Feistritzer C; Wildner SM; Würtinger P; Nachbaur D; Tiede A; Steurer M
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):181-184. PubMed ID: 27152926
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Escape or Fight: Inhibitors in Hemophilia A.
    Merlin S; Follenzi A
    Front Immunol; 2020; 11():476. PubMed ID: 32265927
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of VWF for the success of immune tolerance induction.
    Kreuz W
    Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction.
    Caram C; de Souza RG; de Sousa JC; Araújo Pereira T; do Amaral Cerqueira AM; van der Bom JG; Rezende SM
    Thromb Haemost; 2011 Jan; 105(1):59-65. PubMed ID: 21057702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.